The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for LianBio (LIAN) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.01, or -0.42%, to $2.37. The LianBio has recorded 2,479,281 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Pfizer Opts In to LianBio Rights to Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir in Mainland China, Hong Kong, Macau, and Singapore.
LianBio is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $2.38 and fluctuated between $2.5700 as its day high and $2.0000 as its day low. The current market capitalization of LianBio is $220.22M. A total of 2.82 million shares were traded on the day, compared to an average of 201.49K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, LIAN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 5 BUYs and 0 SELLs from insiders. Insiders purchased 1,238,491 shares during that period but sold 0.
In the most recent transaction, QIAN JIANG sold 2,239 shares of LIAN for 1.65 per share on Jan 03. After the transaction, the SVP, China General Manager now owns 67,349 company shares. In a previous transaction on Aug 18, PERCEPTIVE ADVISORS LLC bought 998,240 shares at 2.40 per share. LIAN shares that Director owns now total 3,728,491.
Among the insiders who bought shares, PERCEPTIVE ADVISORS LLC acquired of 69,000 shares on May 26 at a per-share price of $3.13. This resulted in the Director holding 2,730,251 shares of LIAN after the transaction. In another insider transaction, PERCEPTIVE ADVISORS LLC bought 120,000 shares at $2.63 per share on May 25. Company shares held by the Director now total 2,661,251.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for LIAN in the last 3 months, the mean price target is $7.98 with high estimates of $15.00 and low estimates of $2.92. In terms of 52-week highs and lows, LIAN has a high of $6.24 and a low of $1.07.
As of this writing, LIAN has an earnings estimate of -$0.39 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.32 per share and a lower estimate of -$0.43. The company reported an EPS of -$0.26 in the last quarter, which was 13.30% higher than expectations of -$0.3.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 4 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for LIAN is Buy with a score of 4.67. A total of 2 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.